@misc{oai:repo.qst.go.jp:00066822,
 author = {Yoshii, Yukie and Tashima, Hideaki and Iwao, Yuma and Takuwa, Hiroyuki and Yoshida, Eiji and Wakizaka, Hidekatsu and Yamaya, Taiga and Yoshimoto, Mitsuyoshi and Matsumoto, Hiroki and Zhang, Ming-Rong and Sugyo, Aya and Tsuji, Atsushi and Higashi, Tatsuya and 吉井 幸恵 and 田島 英朗 and 岩男 悠真 and 田桑 弘之 and 吉田 英治 and 脇坂 秀克 and 山谷 泰賀 and 吉本 光喜 and 松本 博樹 and 張 明栄 and 須尭 綾 and 辻 厚至 and 東 達也},
 month = {May},
 note = {Cytoreductive surgery is widely used for the treatment of peritoneal dissemination in clinical practice. However, it is difficult to detect and remove tumors that are located deeply in the peritoneal cavity and easily changing the position during an operation. We have found that a PET probe 64Cu-PCTA-anti-EGFR antibody (cetuximab) highly accumulates in intraperitoneal tumors by intraperitoneal administration. Meanwhile, we have developed the world's first open-type PET system, called "OpenPET". In this system, the detectors were arranged to make open space sufficient enough for surgical procedures. In addition, it can image and track objects with high-resolution PET in real-time. In this study, we examined a feasibility of an OpenPET-guided surgery with 64Cu-PCTA-cetuximab to detect and remove intraperitoneal tumors. Methods: Human colon cancer HCT116 cells stably expressing RFP were intraperitoneally seeded into mice. At 1 week after cell inoculation, 64Cu-PCTA-cetuximab (7.4 MBq / mouse) was administered intraperitoneally. At 24 h later, the OpenPET-guided surgery was performed with a small prototype of the OpenPET. Results: The OpenPET-guided surgery clearly detected tumors located deeply in the peritoneal cavity. Measurement time to accumulate sufficient data to identify the tumors was about 10-30 s. We resected the tumors (≥ 3 mm in diameter) located deeply in the peritoneal cavity while monitoring them with the OpenPET real-time imaging. OpenPET was useful to confirm the presence or absence of residual tumors during an operation. Conclusions: We developed an OpenPET-guided surgery with 64Cu-PCTA-cetuximab to detect and remove intraperitoneal tumors located deeply in the peritoneal cavity. This method could provide a novel strategy of cytoreductive surgery for the patients with peritoneal dissemination from gastrointestinal cancers., 第 13 回日本分子イメージング学会総会・学術集会},
 title = {PET-guided surgery system with 64Cu-PCTA-cetuximab for accurate resection of intraperitoneal tumors in a mice model},
 year = {2018}
}